Regarding goals related to glucose management, tirzepatide increased the proportion of participants achieving fasting glucose levels below 7.2 and 5.6 mmol/l
Microdosing semaglutide (a GLP-1 medication) has been discussed in a clinical commentary, with authors keen to explore its potential benefits
For instance, in one review, researchers looked at 22 studies and concluded that creatine supplementation led to an average strength increase eight percent greater when compared to placebo
According to the Centers for Disease Control (CDC), there are thirteen OACs: adenocarcinoma of the esophagus, post-menopausal breast cancer, colorectal cancer, uterine cancer, gallbladder cancer, upper stomach cancer, kidney cancer, ovarian cancer, pancreatic cancer, thyroid cancer, meningioma, and multiple myeloma
GLP-1:Lani, n = 7
Studies show that patients who discontinue tirzepatide or semaglutide tend to regain a significant portion of lost weight within the first year of cessation